Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma

Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma

Abstract Background The therapeutic IgG1 anti-CD20 antibody, rituximab (RTX), has greatly improved prognosis of many B-cell malignancies. Despite its success, resistance has been reported and detailed knowledge of RTX mechanisms are lacking. Complement-dependent cytotoxicity (CDC) is one important m...

Full description

Bibliographic Details
Main Authors:	Sandra Lara, Juliane Heilig, Alexander Virtanen, Sandra Kleinau
Format:	Article
Language:	English
Published:	BMC 2022-06-01
Series:	BMC Cancer
Subjects:	Rituximab Isotypes B-cell lymphoma 3-dimensional Spheroids Complement-dependent cytotoxicity
Online Access:	https://doi.org/10.1186/s12885-022-09772-1

Similar Items

Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
by: Anna Felberg, et al.
Published: (2020-11-01)

Bispecific mAb<sup>2</sup> Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
by: Katharina Stadlbauer, et al.
Published: (2022-05-01)

The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
by: Alicja Kuźniewska, et al.
Published: (2023-12-01)

The Role of Rituximab in Lymphomas
by: Bertrand Coiffier
Published: (2002-01-01)

A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity
by: Hee-Jeong Youk, et al.
Published: (2022-06-01)

Linfoma hepático primario: Evolución favorable con quimioterapia combinada con rituximab Primary hepatic lymphoma: favorable outcome with chemotherapy plus rituximab
by: I. Serrano-Navarro, et al.
Published: (2008-11-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

Autoantibodies in SLE: Specificities, Isotypes and Receptors
by: Barbara Dema, et al.
Published: (2016-01-01)

Molecular Aspects of Resistance to Immunotherapies—Advances in Understanding and Management of Diffuse Large B-Cell Lymphoma
by: Aleksandra Kusowska, et al.
Published: (2022-01-01)

Complement and hyper acute rejection
by: Al-Rabia Mohammed
Published: (2009-01-01)

Correlation between cellular expression of complement regulatory proteins with depletion and repopulation of B-lymphocytes in peripheral blood of patients with rheumatoid arthritis treated with rituximab
by: Daniela Viecceli, et al.

Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells via Autologous B Cells
by: Chao Niu, et al.
Published: (2021-05-01)

Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies
by: Vibor Milunović, et al.
Published: (2017-01-01)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
by: Peng‐Fei Zhang, et al.
Published: (2020-08-01)

The immunopathology of human schistosomiasis-III: immunoglobulin isotype profiles and response to praziquantel
by: Romelia M Ramírez, et al.
Published: (1996-10-01)

Regulation of Tubulin Gene Expression: From Isotype Identity to Functional Specialization
by: Ivana Gasic
Published: (2022-05-01)

Adding rituximab to chemotherapy for diffuse large B-cell lymphoma patients in Indonesia: a cost utility and budget impact analysis
by: Septiara Putri, et al.
Published: (2022-04-01)

Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
by: Vít Procházka, et al.
Published: (2020-07-01)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
by: Steven Habbous, et al.
Published: (2020-10-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

Experience of using rituximab for recurrent non-Hodgkin lymphoma in elderly patients of the Orel region
by: R. A. Golubenko, et al.
Published: (2014-07-01)

CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
by: Margaret A. Lindorfer, et al.
Published: (2013-11-01)

Red cell antibodies resulting in false-positive complement-dependent cytotoxicity cross-match: A unique case
by: Rajesh B Sawant, et al.
Published: (2021-01-01)

Intralesional and systemic rituximab in the treatment of primary cutaneous B‐cell lymphoma
by: Jake G. Besch‐Stokes, et al.
Published: (2023-12-01)

Falsely positive HIV test due to Interference by heterophile antibodies in a patient with Mantle cell lymphoma treated with Rituximab
by: Mariano Fiorenza, et al.
Published: (2022-09-01)

Rituximab in the treatment of nodal Bcell marginal zone lymphoma, primary Sjogren’s syndrome and autoimmune hepatitis
by: O A Logvinenko, et al.
Published: (2008-10-01)

Rituximab therapy for systemic manifestations and MALT lymphomas of the parotid gland in Sjögren's disease: Preliminary data
by: O A Logvinenko, et al.
Published: (2012-12-01)

Intravitreal rituximab for the treatment of a secondary intraocular relapse of a large B-cell lymphoma
by: Jose J. Echegaray, et al.
Published: (2018-03-01)

Microtubules in Microorganisms: How Tubulin Isotypes Contribute to Diverse Cytoskeletal Functions
by: Abesh Bera, et al.
Published: (2022-07-01)

The Role of Rituximab in the Treatment of Primary Central Nervous System Lymphoma
by: Ruben Van Dijck, et al.
Published: (2021-04-01)

Enhanced pro-apoptotic activity of rituximab through IBTK silencing in non-Hodgkin lymphoma B-cells
by: Eleonora Vecchio, et al.
Published: (2024-02-01)

Editorial: Complement and Immunotherapeutics
by: Marcin Okrój, et al.
Published: (2021-02-01)

Rituximab-induced interstitial pneumonitis in patient with non-Hodgkin lymphoma: a clinical case
by: Nikolai A. Ognerubov, et al.
Published: (2022-08-01)

CD46 and CD59 inhibitors enhance complement-dependent cytotoxicity of anti-CD38 monoclonal antibodies daratumumab and isatuximab in multiple myeloma and other B-cell malignancy cells
by: Hongjie Wang, et al.
Published: (2024-12-01)

Making Rituximab Directly Cytotoxic for Substantial Improvement in Therapeutic Efficacy
by: Xinjian Chen
Published: (2018-08-01)

Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab
by: Christian Menzer, et al.
Published: (2022-09-01)

Follicular Lymphoma
by: İrfan Yavaşoğlu
Published: (2015-02-01)

Leuconostoc sp. Meningitis in a Patient Treated with Rituximab for Mantle Cell Lymphoma
by: Hrvoje Holik, et al.
Published: (2015-07-01)

Isotype Visualizations. A Chance for Participation & Civic Education
by: Eva Mayr, et al.
Published: (2014-12-01)